168 related articles for article (PubMed ID: 34329992)
41. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
Gangjee A; Adair O; Queener SF
J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
[TBL] [Abstract][Full Text] [Related]
42. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
[TBL] [Abstract][Full Text] [Related]
43. New imidazolone derivatives comprising a benzoate or sulfonamide moiety as anti-inflammatory and antibacterial inhibitors: Design, synthesis, selective COX-2, DHFR and molecular-modeling study.
Metwally NH; Mohamed MS
Bioorg Chem; 2020 Jun; 99():103438. PubMed ID: 31796216
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis, anticancer, and antibacterial evaluation of some quinazolinone-based derivatives as DHFR inhibitors.
Osman EO; Emam SH; Sonousi A; Kandil MM; Abdou AM; Hassan RA
Drug Dev Res; 2023 Aug; 84(5):888-906. PubMed ID: 37052308
[TBL] [Abstract][Full Text] [Related]
45. Synthesis of Benzo[d]imidazo[2,1-b]thiazole-Propenone Conjugates as Cytotoxic and Apoptotic Inducing Agents.
Shaik SP; Reddy TS; Sunkari S; Rao AVS; Babu KS; Bhargava SK; Kamal A
Anticancer Agents Med Chem; 2019; 19(3):347-355. PubMed ID: 30479221
[TBL] [Abstract][Full Text] [Related]
46. Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
Richardson ML; Croughton KA; Matthews CS; Stevens MF
J Med Chem; 2004 Jul; 47(16):4105-8. PubMed ID: 15267250
[TBL] [Abstract][Full Text] [Related]
47. Triazine-benzimidazole hybrids: anticancer activity, DNA interaction and dihydrofolate reductase inhibitors.
Singla P; Luxami V; Paul K
Bioorg Med Chem; 2015 Apr; 23(8):1691-700. PubMed ID: 25792141
[TBL] [Abstract][Full Text] [Related]
48. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
[TBL] [Abstract][Full Text] [Related]
49. Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
Ma X; Chui WK
Bioorg Med Chem; 2010 Jan; 18(2):737-43. PubMed ID: 20036565
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and biological evaluation of imidazo[2,1-b]thiazole-benzimidazole conjugates as microtubule-targeting agents.
Baig MF; Nayak VL; Budaganaboyina P; Mullagiri K; Sunkari S; Gour J; Kamal A
Bioorg Chem; 2018 Apr; 77():515-526. PubMed ID: 29459129
[TBL] [Abstract][Full Text] [Related]
51. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
52. Design and synthesis of 1,2,3-triazolo linked benzo[d]imidazo[2,1-b]thiazole conjugates as tubulin polymerization inhibitors.
Shaik SP; Vishnuvardhan MVPS; Sultana F; Subba Rao AV; Bagul C; Bhattacharjee D; Kapure JS; Jain N; Kamal A
Bioorg Med Chem; 2017 Jul; 25(13):3285-3297. PubMed ID: 28462842
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, antitumor activity and mechanism of action of novel 1,3-thiazole derivatives containing hydrazide-hydrazone and carboxamide moiety.
He H; Wang X; Shi L; Yin W; Yang Z; He H; Liang Y
Bioorg Med Chem Lett; 2016 Jul; 26(14):3263-3270. PubMed ID: 27262600
[TBL] [Abstract][Full Text] [Related]
54. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
Singh P; Kaur M; Sachdeva S
J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Gangjee A; Adair OO; Queener SF
J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
[TBL] [Abstract][Full Text] [Related]
56. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
[TBL] [Abstract][Full Text] [Related]
57. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
[TBL] [Abstract][Full Text] [Related]
58. Non-classical antifolates, 5-(N-phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and 2,4-Diamino-6(5H)-oxopyrimidines, synthesis and antitumor studies.
Huang YL; Lin CF; Lee YJ; Li WW; Chao TC; Bacherikov VA; Chen KT; Chen CM; Su TL
Bioorg Med Chem; 2003 Jan; 11(1):145-57. PubMed ID: 12467717
[TBL] [Abstract][Full Text] [Related]
59. Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity.
El-Sattar NEAA; Badawy EHK; AbdEl-Hady WH; Abo-Alkasem MI; Mandour AA; Ismail NSM
Chem Pharm Bull (Tokyo); 2021; 69(1):106-117. PubMed ID: 33390512
[TBL] [Abstract][Full Text] [Related]
60. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
